In February 2022, we announced that Emily’s Entourage (EE) awarded $440,000 in funding for two new grants to advance cystic fibrosis (CF) research and drug development. Today, we are thrilled to share that EE has awarded an additional $178,882 to a third grant recipient, Mitochon Pharmaceuticals, Inc., to advance research into mitochondrial dysfunction in those with CF.
Additional information on this grant is available below.
Therapeutic utility of MP-101 for cystic fibrosis
John G. Geisler, PhD, CSO and co-founder (left)
Robert Alonso, MBA, CEO and co-founder (right)
Mitochon Pharmaceuticals, Inc.
Mitochondrial dysfunction is an often overlooked issue in people with CF. It is marked by impaired energy production and the generation of huge levels of free radicals that are toxic to all cells in the body. Mitochon’s work represents a novel approach for CF in its use of a mitochondrial modulator, MP-101, to reduce free radical production and mitochondrial calcium overload, thereby reducing inflammatory responses and consequent tissue damage. MP-101 will be tested in a ferret model of CF and, if successful, could be tested in patients with CF.
Learn about the other two round six grant recipients, announced in February 2022, whose work focuses on the development of a new nonsense mutation ferret model and a novel form of gene therapy using lipid nanoparticles.
We are grateful to all of the dedicated scientists who are leading the charge to fill critical unmet needs for all people with CF fast — nobody left behind! View a comprehensive listing of all awarded research grants.